What is King Pharmaceuticals's all other lines — year 7?

King Pharmaceuticals (KG) reported all other lines — year 7 of 1.2% in Q4 2025.

What does all other lines — year 7 mean?

This metric represents the financial contribution of miscellaneous or non-core business segments for the seventh fiscal year. It aggregates results from secondary product lines that are not significant enough to be reported as primary segments. This helps in understanding the broader operational scope and the performance of the company's diversified business portfolio.

King Pharmaceuticals KG All other lines — Year 7

Other product segments

General Liability

8.3%—

European Hospital Liability

7%—

Commercial Auto Liability

5.2%—

International

0.8%—

Similar metrics at other companies

SPNTOther — Year 7

0.5%-0.3pp

GLREFinancial — Year 7

2.4%—

ACGLMulti-line and other specialty — Year Seven

2.1%+0.4pp

HWMOther — Sales

$102M+21.4%

TRG

TRGPAll Other Segments — Revenue

-$110.3M+55.7%

SPNTOther — Year 10

0%—

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-67.6%

Enterprise value$184.93M-50.0%

P/E1.2×—

P/S1.6×-24.3×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ShortdurationInsuranceContractsHistoricalClaimsDurationYearSeven.

The official record: King Pharmaceuticals’s 10-K, filed March 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's all other lines — year 7.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's all other lines — year 7?: King Pharmaceuticals (KG) reported all other lines — year 7 of 1.2% in Q4 2025.
What does all other lines — year 7 mean?: This metric represents the financial contribution of miscellaneous or non-core business segments for the seventh fiscal year. It aggregates results from secondary product lines that are not significant enough to be reported as primary segments. This helps in understanding the broader operational scope and the performance of the company's diversified business portfolio.